Absolute neutrophil count (ANC) >= 1 x 10^9/L within 30 days of day 1 of study
Absolute neutrophil count (ANC) >= 1.5 10^9/L, within 28 days prior to administration of study treatment
Absolute neutrophil count (ANC) >= 1.5 x 10^9/L measured within 28 days prior to randomization
Absolute neutrophil count >= 1500/uL; Note: no transfusions are permitted 7 days prior to laboratory studies to determine eligibility
Absolute neutrophil count (ANC) >= 1.5 x 10^9/L, measured within 28 days prior to administration of study treatment
Absolute neutrophil count (ANC) >= 1,500/ul without the use of hematopoietic growth factors (within 14 days of treatment initiation)
Absolute neutrophil count (ANC) >= 1,500/mm^3 (1.5 x 10^9/L) must be met within 28 days of cycle 1 day 1 (C1D1)
Absolute neutrophil count (ANC) >= 1.5 X 10^9/L within 14 days of starting cycle 1 day 1 treatment
Within 10 (except as noted) days of planned treatment initiation: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1500 per mm^3)
Absolute neutrophil count (ANC) >= 1500/uL performed within 30 days prior to the date of registration
Absolute neutrophil count >= 1,500/microliters, completed within 14 days prior to the date of registration
Within 28 days of study registration: Absolute neutrophil (segmented and bands) count (ANC) >= 1.0 x 10^9/L
Absolute neutrophil count (ANC) >= 1,500/uL within 14 days prior to first dose of protocol-indicated treatment.
Absolute neutrophil count (ANC) < 1000/mm^3, per principal investigator (PI) discretion if thought to be related to underlying myeloma
Within 10 days prior to the start of study treatment: Absolute neutrophil count (ANC) >= 1500/uL
Within 7 days of enrollment and with 24 hours (h) of starting lymphodepleting chemotherapy: Absolute neutrophil count (ANC) >= 1000/mm^3.
Absolute neutrophil count (ANC) >= 1,000/mm^3, performed within 14 days prior to day 1 of protocol therapy\r\n* Filgrastim can be given prior to enrollment to achieve target ANC >= 1000/uL
Within 28 days prior to treatment start: Absolute neutrophil count (ANC) >= 1500/ul
Obtained within 21 days prior to cycle 1, day 1: absolute neutrophil count (ANC) >= 1 x 10^9/L
Absolute neutrophil count (ANC) > 1.5 k/cumm
STUDY TREATMENT: Absolute neutrophil count (ANC) >= 1500 cells/uL within 14 days prior to the first study treatment.
Obtained within 14 days of the first study treatment: Absolute neutrophil count (ANC) > 1500 cells/ul
Absolute neutrophil count (ANC) > 1,000/uL unless disease-related (due to marrow infiltration or splenomegaly)
Within 7 days prior to administration of study treatment: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (unless due to bone marrow infiltration by tumor, in which case ANC > 1,000/mm^3 is allowed).
Absolute neutrophil count (ANC) >= 1,000 cells/mm^3 (1.0 x 10^9/L) must be met during screening (within 21 days) and also prior to study drug administration on cycle 1 day 1
Obtained within 14 days of the first study treatment: Absolute neutrophil count (ANC) > 1500 cells/ul
Within 7 days (+ 3 day window) of enrollment: Absolute neutrophil count (ANC) >= 1.0 x 10^9/L (> 1000 per mm^3)
Obtained within 14 days prior to the first study treatment (cycle 1, day 1): absolute neutrophil count (ANC) >= 1500 cells/u
Within 14 days of the first study treatment: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
Absolute neutrophil count (ANC) ?1500/millimeters cubed (mm^3) (?1.5 × 10^3/microliters [µL])
Within 14 days prior to cycle 1 day 1 of treatment: Absolute neutrophil count (ANC) >= 1,000 K/mm^3
Absolute neutrophil count (ANC) >= 1.5 x 10^9/L, measured within 28 days prior to administration of study treatment
Subjects with an absolute neutrophil count (ANC) of equal to or higher than 0.5 x 10^9 at the screening visit
Within 14 days prior to the first study treatment (cycle 1, day 1): Absolute neutrophil count (ANC) >= 1500 cells/uL
Absolute neutrophil count (ANC) >= 1000/uL, within 14 days of study registration (within 30 days for pulmonary and cardiac assessments)
Absolute neutrophil count (ANC) >= 1500 cells/uL (obtained within 28 days prior to first study treatment)
Absolute neutrophil count (ANC) ? 1500 cells/uL within 14 days prior to the first study treatment (cycle 1, day 1)
To be performed within 10 business days prior to day 1: Absolute neutrophil count (ANC) >= 1,000/mm^3; filgrastim can be given prior to enrollment to achieve target ANC >= 1000/uL
Absolute neutrophil count (ANC) >= 1.5 X 10^9/L, within 14 days start of study start
Absolute neutrophil count (ANC) < 1000/mm^3 unless lymphoma, KSHV-MCD, or KICS-related
Absolute neutrophil count (ANC) >= 1.0 x 10^9/L\r\n* By automated or manual review, whichever is greatest
Absolute neutrophil count (ANC) or atypical glandular cell (AGC) >= 1500 per uL
Absolute neutrophil count (ANC) < 1,000/mm^3 (Unit of International System of Units [SI] units 109/L)
Absolute neutrophil count (ANC) >= 1 x 10^9 (International System [SI] units 10^9/L) (with or without filgrastim [G-CSF])
Absolute neutrophil count (ANC) >= 1.5 K/CUMM
Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (measured within 28 days prior to administration of study treatment)
INCLUSION CRITERIA FOR ADDITIONAL PTCy-MILs INFUSION AT RELAPSE: Absolute neutrophil count (ANC) >= 1,500/uL
TREATMENT: Engrafted post-transplant (absolute neutrophil count [ANC] > 500 for at least 3 consecutive days) and ANC > 500 at the time of infusion
Evidence of neutrophil engraftment defined as the absolute neutrophil count (ANC) > 0.5 x 10^3/for 3 consecutive days
Absolute neutrophil count >= 1,500/uL obtained no more than 28 days prior to the start of neoadjuvant endocrine therapy
Absolute neutrophil count >= 1,500 cells/uL (to be performed within 7 days prior to start of study treatment)
Absolute neutrophil count (ANC) >= 1.0 x 10^9/L within 14 days prior to starting therapy
Treatment indicated based on demonstration of at least one of the following no more than 4 weeks from the time of enrollment, and no less than 6 months after prior cladribine and no less than 4 weeks after other prior treatment, if applicable:\r\n* Neutropenia (absolute neutrophil count [ANC] < 1000 cells/ul)\r\n* Anemia (hemoglobin [Hgb] < 10g/dL)\r\n* Thrombocytopenia (platelets [Plt] < 100,000/ul)\r\n* Absolute lymphocyte count (ALC) of > 5,000 cells/uL\r\n* Symptomatic splenomegaly\r\n* Enlarging lymph nodes > 2 cm\r\n* Repeated infections requiring oral or i.v. antibiotics
Absolute neutrophil count (ANC) >= 1.5 x 10^9/L within 28 days prior to administration of study treatment.
Within 28 days prior to administration of study treatment: Absolute neutrophil count (ANC) ? 1.5 x 10^9/L
Within 14 days of first dose of study drug: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
Within 14 days of study drug(s) initiation: Absolute neutrophil count (ANC) >=1500/·L.
Within 14 days prior to the first study treatment (cycle 1, day 1): Absolute neutrophil count (ANC) >= 1500 cells/uL.
Within 14 days prior to first dose of study drug treatment: Absolute neutrophil count (ANC) >= 1.5 x 109/L
Measured within 28 days prior to administration of study treatment: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
Obtained within 14 days (or as stipulated) prior to study drug (treatment) administration: absolute neutrophil count (ANC) ? 1000 cells/ul (growth factor cannot be used within the previous 5 days)
Absolute neutrophil count (ANC) >= 1500/uL, specimens must be collected within 10 days prior to the start of study treatment
Absolute neutrophil count (ANC) ? 1.0 × 109/L within 14 days prior to randomization
Absolute neutrophil count (ANC) >= 1.5 x 10^9/L, measured within 28 days prior to administration of study treatment
Absolute neutrophil count (ANC) < 750/uL, if these cytopenias are not judged by the investigator to be due to underlying disease (i.e. potentially reversible with anti-neoplastic therapy)
Absolute neutrophil count (ANC) must be > 750/mm^3 (unless due to underlying disease in which case there is no grade restriction)
Within 14 days of study start: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
Absolute neutrophil count (ANC) >= 1.5 x 10^9 (SI units 10^9/L)
Prior to cyclophosphamide and T cell infusions: absolute neutrophil count (ANC) =< 1000
Within 14 days prior to the first study treatment (cycle 1, day 1): Absolute neutrophil count (ANC) >= 1500 cells/uL
Absolute Neutrophil Count (ANC) <1000 within 8 weeks prior to initial cryoablation procedure.
Within 30 days prior to initiation of protocol treatment: Absolute neutrophil count (ANC) >= 1500/mm^3
Obtained within 14 days prior to the first study treatment (cycle 1, day 1); absolute neutrophil count (ANC) ? 1500 cells/uL
Absolute neutrophil count (ANC) >= 1500/mcl (filgrastim [G-CSF] is allowed) (must be within 7 days of MLA)
Absolute neutrophil (segmented and bands) count (ANC) >= 1.0 x 10^9/L
Absolute neutrophil count (ANC) >= 1,500/ul (unless due to bone marrow infiltration by tumor in which case ANC >= 500/ml are allowed)
Absolute neutrophil (segmented and bands) count (ANC) >= 1.0 x 10^9/L
Absolute neutrophil count (ANC, calculated as the absolute number of neutrophils and bands) >= 1.5 x 10^9 cells/L
Absolute neutrophil count (ANC) >= 1500 cells/uL (obtained within 14 days prior to the first study treatment [course 1, day 1])
Absolute neutrophil count (ANC) of >= 1,500/microliters within 90 days prior to registration
Absolute neutrophil count (ANC) > 1000 unless impairment due to organ involvement by lymphoma
Absolute neutrophil count (ANC) must be > 750/mm^3 (unless due to underlying disease in which case there is no grade restriction)
Within 14 days prior to first study treatment: Absolute neutrophil count (ANC) >= 1500/10^9 dL
Absolute neutrophil count (ANC) > 1,500 cells/ul within 14 days prior to treatment initiation
Patients must have absolute neutrophil count (ANC) >= 1000/uL; Neupogen can be given prior to start of SGN-35 (brentuximab vedotin) and during SGN-35 treatment to achieve target ANC >= 1000/uL
Absolute neutrophil count (ANC) < 1,000/mm^3 (International System of Units [SI] units 109/L)
Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 (International System of Units [SI] units 1.5 x 10^9/L)
Absolute neutrophil count (ANC) >= 1500 cells/uL (obtained within 28 days prior to the first study treatment)
Patients with absolute neutrophil count (ANC) >= 1,000/uL; the most recent ANC level taken within 60 days prior to study enrollment will be considered
Subjects with an absolute neutrophil count (ANC) of equal to or higher than 0.5 x 10^9/L at the screening visit
Absolute neutrophil count (ANC) >= 1500, unless felt to be secondary to underlying mantle cell lymphoma
Anticipated or documented prolonged neutropenia (absolute neutrophil count [ANC] < 500/mm^3 [0.5 x 10^9/L]) at baseline or likely to develop within 3 to 5 days and lasting for at least 7 days due to:
Patients must have or be anticipated to have neutropenia (absolute neutrophil count [ANC] < 0.5 x 10^9/L) (75) for >= 7 days as a result of treatment of their AML/MDS
Absolute neutrophil count (ANC) >= 1,500/uL, obtained within 14 days prior to treatment start
Measured within 28 days prior to administration of study treatment: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
Absolute neutrophil count (ANC) >= 1.5 X 10^9/L (evaluated within 28 days of\r\nrandomization)
Absolute neutrophil count (ANC) >= 1.5 x 10^9/L, within 2 weeks prior to study start
